TransCode Therapeutics (NASDAQ: RNAZ) announced it will host its first live virtual R&D webcast on June 18, 2026, to provide strategic, scientific and clinical updates across its development pipeline. The presentation will be anchored by the company's recently initiated Phase 2a clinical trial of TTX-MC138 in circulating tumor DNA-positive colorectal cancer and will also include portfolio updates and discussion of its broader investment thesis.
TransCode Therapeutics is a clinical stage company pioneering immuno-oncology and RNA therapeutic treatments for high risk and advanced cancers. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.
The upcoming webcast marks the company's first R&D-focused investor event, signaling a push to engage the investment community as it advances its lead candidate into mid-stage trials. The Phase 2a study targets colorectal cancer patients with circulating tumor DNA, a biomarker that indicates active disease and higher risk of recurrence. Success in this trial could validate TransCode's approach of targeting microRNA-10b, which is linked to metastatic spread across multiple cancer types.
For business and technology leaders, the implications extend beyond oncology. TransCode's platform represents a convergence of RNA therapeutics and precision medicine, leveraging biomarkers to select patients most likely to benefit. If TTX-MC138 demonstrates efficacy, it could pave the way for RNA-based treatments in other metastatic cancers, potentially disrupting existing treatment paradigms dominated by immunotherapy and chemotherapy. The company's pipeline includes additional candidates designed to harness the immune system, further broadening its potential impact.
Investors and industry observers will be watching for data on safety, tolerability, and early signs of efficacy from the Phase 2a trial. The webcast will also provide updates on TransCode's broader portfolio, which aims to address high unmet needs in oncology. For those tracking the RNA therapeutics space, TransCode's progress offers a lens into the challenges and opportunities of targeting non-coding RNA.
More information about TransCode and its news can be found in the company's newsroom at https://ibn.fm/RNAZ. The full press release about the webcast is available at https://ibn.fm/u5AfW.
